Guangdong Biolight Meditech Co., Ltd. (300246.SZ)
CNY 7.6
(-0.78%)
CNY 7.6
(-0.78%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 36.24 Million CNY | 54.74% |
| 2022 | 95.08 Million CNY | -36.73% |
| 2021 | 135.96 Million CNY | -67.86% |
| 2020 | 454.25 Million CNY | 289.29% |
| 2019 | 117.87 Million CNY | 7.14% |
| 2018 | 107.62 Million CNY | 2.74% |
| 2017 | 104.71 Million CNY | -0.14% |
| 2016 | 107.83 Million CNY | 89.92% |
| 2015 | 45.98 Million CNY | 9.8% |
| 2014 | 51.15 Million CNY | 19.45% |
| 2013 | 41.67 Million CNY | -11.4% |
| 2012 | 47.53 Million CNY | 14.62% |
| 2011 | 41.64 Million CNY | 7.3% |
| 2010 | 40.35 Million CNY | 43.87% |
| 2009 | 26.11 Million CNY | 48.05% |
| 2008 | 13.7 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 10.07 Million CNY | 109.52% |
| 2024 Q2 | 5.32 Million CNY | -47.14% |
| 2024 Q3 | 885.45 Thousand CNY | -83.37% |
| 2023 Q4 | -11.54 Million CNY | -181.57% |
| 2023 Q1 | 41.43 Million CNY | 132.86% |
| 2023 Q2 | 41.56 Million CNY | 0.32% |
| 2023 FY | - CNY | 54.74% |
| 2023 Q3 | 14.16 Million CNY | -65.93% |
| 2022 FY | - CNY | -36.73% |
| 2022 Q3 | 10.5 Million CNY | 335.22% |
| 2022 Q1 | 17.81 Million CNY | 272.28% |
| 2022 Q2 | -4.46 Million CNY | -125.07% |
| 2022 Q4 | 17.79 Million CNY | 69.39% |
| 2021 Q2 | 44.51 Million CNY | 33.58% |
| 2021 Q1 | 33.32 Million CNY | -24.33% |
| 2021 Q3 | 23.67 Million CNY | -46.81% |
| 2021 Q4 | 4.78 Million CNY | -79.79% |
| 2021 FY | - CNY | -67.86% |
| 2020 FY | - CNY | 289.29% |
| 2020 Q4 | 44.04 Million CNY | -51.03% |
| 2020 Q3 | 89.93 Million CNY | -64.15% |
| 2020 Q2 | 250.83 Million CNY | 362.4% |
| 2020 Q1 | 54.24 Million CNY | 133.78% |
| 2019 Q4 | 23.2 Million CNY | -39.65% |
| 2019 FY | - CNY | 7.14% |
| 2019 Q1 | 21.98 Million CNY | -1.11% |
| 2019 Q2 | 19.8 Million CNY | -9.88% |
| 2019 Q3 | 38.45 Million CNY | 94.12% |
| 2018 Q3 | 24.35 Million CNY | 7.32% |
| 2018 Q2 | 22.69 Million CNY | -13.17% |
| 2018 Q4 | 22.22 Million CNY | -8.75% |
| 2018 FY | - CNY | 2.74% |
| 2018 Q1 | 26.13 Million CNY | 69.09% |
| 2017 Q4 | 15.45 Million CNY | -40.85% |
| 2017 FY | - CNY | -0.14% |
| 2017 Q1 | 22.19 Million CNY | -23.47% |
| 2017 Q3 | 26.13 Million CNY | -26.26% |
| 2017 Q2 | 35.43 Million CNY | 59.67% |
| 2016 Q2 | 25.88 Million CNY | 39.09% |
| 2016 FY | - CNY | 89.92% |
| 2016 Q1 | 18.61 Million CNY | -12.65% |
| 2016 Q4 | 28.99 Million CNY | 20.56% |
| 2016 Q3 | 24.05 Million CNY | -7.09% |
| 2015 Q2 | 2.98 Million CNY | -50.38% |
| 2015 Q4 | 21.3 Million CNY | 14.9% |
| 2015 Q3 | 18.54 Million CNY | 520.37% |
| 2015 FY | - CNY | 9.8% |
| 2015 Q1 | 6.02 Million CNY | -72.2% |
| 2014 Q2 | 11.55 Million CNY | 58.03% |
| 2014 Q3 | 5.36 Million CNY | -53.58% |
| 2014 Q4 | 21.66 Million CNY | 303.97% |
| 2014 FY | - CNY | 19.45% |
| 2014 Q1 | 7.31 Million CNY | -33.39% |
| 2013 Q1 | 4.83 Million CNY | -80.68% |
| 2013 Q3 | 9.23 Million CNY | -23.5% |
| 2013 Q4 | 10.97 Million CNY | 18.87% |
| 2013 FY | - CNY | -11.4% |
| 2013 Q2 | 12.07 Million CNY | 149.8% |
| 2012 Q1 | 2 Million CNY | -85.91% |
| 2012 Q4 | 25.01 Million CNY | 168.36% |
| 2012 Q3 | 9.32 Million CNY | 18.05% |
| 2012 FY | - CNY | 14.62% |
| 2012 Q2 | 7.89 Million CNY | 293.09% |
| 2011 Q1 | 2.58 Million CNY | -84.08% |
| 2011 FY | - CNY | 7.3% |
| 2011 Q2 | 17.13 Million CNY | 561.77% |
| 2011 Q4 | 14.25 Million CNY | 174.63% |
| 2011 Q3 | 5.19 Million CNY | -69.7% |
| 2010 Q3 | 8.33 Million CNY | 0.0% |
| 2010 Q4 | 16.26 Million CNY | 95.23% |
| 2010 FY | - CNY | 43.87% |
| 2009 FY | - CNY | 48.05% |
| 2008 FY | - CNY | 0.0% |